Company / Free Cash Flow
UroGen Pharma Ltd. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$162.7M
FY2025
5-year range
-$162.7M / -$76.6M
FY2021-FY2025
Trend
-112.5%
vs FY2024
Sector context
#134 of 194
Health Care
What the data says
At -$163M, UroGen Pharma Ltd.'s free cash flow ranks #134 of 194 in the Health Care sector. Free Cash Flow has fluctuated over the past 10 years, ranging from -$163M in FY2025 to $3M in FY2016.
Based on SEC 10-K filings.
-$163M in FY2025.
Declined from -$88M to -$163M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#134 of 194 in Health CareTop 69% of 194This company -$162.7M Sector average $470.6M
▼
-134.6% below sector average
Key checks
Key Insights
- In FY2025, free cash flow decreased 112.5% year-over-year.
- Ranks #134 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$162.7M | -112.5% |
| FY2024 | -$76.6M | +12.8% |
| FY2023 | -$87.8M | -2.5% |
| FY2022 | -$85.6M | +0.0% |
| FY2021 | -$85.6M | -20.0% |
| FY2020 | -$71.3M | -625.1% |
| FY2019 | -$9.8M | +74.0% |
| FY2018 | -$37.9M | -285.1% |
| FY2017 | -$9.8M | -381.6% |
| FY2016 | $3.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026